May 28, 2025

Statins Recommended for HIV Patients at Risk for Heart Disease

Guidelines from the Department of Health and Human Services recommend statins as primary prevention for people with HIV aged 40 to 75 years who have a 10-year ASCVD risk of 5% or higher.

Conexiant

May 28, 2025

Ranya Habash: Power List Perspectives

Our Power Lister winners explore the major trends in their field, and the seismic impact AI and machine learning is having on the profession

The Ophthalmologist

May 27, 2025

ADA calls for ERISA, Medicare Advantage reform

The ADA is offering its perspective on how certain anticompetitive regulations impact the dental sector.

ADA News

May 23, 2025

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are availa...

The ASCO Post

May 23, 2025

Careers Uncovered: Chief Medical Officer

Rob Monroe, CMO at Leica Biosystems, shares his experiences of innovation and leadership in the diagnostic technologies sector

The Pathologist

May 23, 2025

CDC urges health care providers to stay alert for measles cases

Measles continues to spread in the U.S., as the total number of cases in 2025 is already more than three times the total for all of 2024.

ADA News

May 23, 2025

The Legal Impacts on Oncology Care of Prohibiting Diversity, Equity, and Inclusion Efforts

In January 2025, the Trump Administration issued executive orders asserting opposition to diversity, equity, and inclusion (DEI) programs on the federal level and rescinding Biden Administration order...

The ASCO Post

May 22, 2025

Cardiogenic Shock in Women: Treatment Disparities Persist

New expert consensus statement reveals that women with cardiogenic shock face significant treatment disparities and outlines evidence-based recommendations for improving outcomes.

Conexiant

May 22, 2025

Combination Therapy for Newly Diagnosed, BRCA-Nonmutated, Advanced Epithelial Ovarian Cancer

The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inh...

The ASCO Post